Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma

Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter duratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Cesar, Catamero, Donna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184840/
https://www.ncbi.nlm.nih.gov/pubmed/37197721
http://dx.doi.org/10.6004/jadpro.2023.14.3.14
_version_ 1785042221207126016
author Rodriguez, Cesar
Catamero, Donna
author_facet Rodriguez, Cesar
Catamero, Donna
author_sort Rodriguez, Cesar
collection PubMed
description Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma.
format Online
Article
Text
id pubmed-10184840
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-101848402023-05-16 Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma Rodriguez, Cesar Catamero, Donna J Adv Pract Oncol Meeting Reports Therapeutic options for patients with multiple myeloma have multiplied in the past decade. However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma is characterized by genetic and cytogenetic alterations that drive resistance and result in progressively shorter durations of remission to each subsequent therapy. At JADPRO Live 2022, presenters discussed the multifactorial process for choosing the right therapy for a particular patient and strategies to manage unique treatment complications associated with novel treatment modalities used for patients with relapsed/refractory multiple myeloma. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184840/ /pubmed/37197721 http://dx.doi.org/10.6004/jadpro.2023.14.3.14 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Rodriguez, Cesar
Catamero, Donna
Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
title Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
title_full Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
title_fullStr Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
title_full_unstemmed Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
title_short Novel Treatments for Patients With Relapsed/Refractory Multiple Myeloma
title_sort novel treatments for patients with relapsed/refractory multiple myeloma
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184840/
https://www.ncbi.nlm.nih.gov/pubmed/37197721
http://dx.doi.org/10.6004/jadpro.2023.14.3.14
work_keys_str_mv AT rodriguezcesar noveltreatmentsforpatientswithrelapsedrefractorymultiplemyeloma
AT catamerodonna noveltreatmentsforpatientswithrelapsedrefractorymultiplemyeloma

Ejemplares similares